AMD in Patiala — Understanding the Leading Cause of Vision Loss in Older Adults

Why age-related macular degeneration (AMD) needs careful monitoring and early treatment

As Patiala's population ages, age-related macular degeneration (AMD) is increasingly encountered in the clinical practice of eye care specialists in the region. AMD is the leading cause of severe, irreversible central vision loss in people over 60 in the developed world, and its prevalence is rising in India as the population ages and life expectancy improves. At Garg Eye Hospital Patiala, we provide comprehensive AMD assessment, monitoring, and treatment — including the critically important anti-VEGF intravitreal injection therapy for wet AMD.

Understanding the difference between dry and wet AMD is essential for patients and their families. Many patients are told they have "dry AMD" and given the impression that nothing can be done. While this is partly true — there is no approved treatment that reverses early dry AMD — the picture is more complex. Intermediate dry AMD can progress to advanced dry AMD (geographic atrophy) or convert to wet AMD, the latter requiring urgent treatment. Regular monitoring at Garg Eye Hospital Patiala catches this conversion before irreversible vision loss occurs.

The Macula — Why Central Vision Matters So Much

The macula is a small but extraordinarily important area in the centre of the retina, approximately 5mm in diameter. Despite occupying only about 2% of the total retinal surface, it is responsible for essentially all of the sharp, detailed central vision we rely on for reading, recognising faces, watching television, driving, and performing fine tasks. The fovea — the very centre of the macula — has the highest density of cone photoreceptors in the entire eye, providing the sharpest possible central visual acuity.

When AMD damages the macula, patients lose the ability to see fine detail centrally. Early AMD causes subtle changes — difficulty reading small print, increased need for bright light, reduced contrast sensitivity. As AMD advances, the central visual field develops a scotoma — a blurred, distorted, or completely blank area in the centre of vision. Peripheral vision generally remains intact in AMD (unlike glaucoma, which destroys peripheral vision first), meaning patients do not become completely blind from AMD — they retain the ability to navigate their environment — but lose the central vision needed for the activities of daily life that matter most.

The Amsler Grid — Self-Monitoring at Home

Patients with known AMD or those at high risk (family history, intermediate AMD) are given an Amsler grid — a simple grid of horizontal and vertical lines with a central fixation point — for home monitoring. Looking at the Amsler grid daily with each eye individually, at reading distance, allows early detection of new metamorphopsia (waviness or distortion of the lines) or central scotoma development.

Any new distortion or blank area noticed on the Amsler grid should prompt immediate contact with Garg Eye Hospital Patiala. This kind of early warning system allows wet AMD — which can cause rapid vision loss over days to weeks if untreated — to be caught and treated at the earliest possible stage, before irreversible photoreceptor damage has accumulated. Our patients are educated on Amsler grid use at every AMD monitoring visit.

Anti-VEGF Treatment for Wet AMD — How Often and How Long?

One of the most common questions from AMD patients and their families at Garg Eye Hospital Patiala concerns the frequency and duration of anti-VEGF injections. This is understandable — the prospect of indefinite, frequent intravitreal injections is daunting, and patients reasonably want to know when treatment ends.

The honest answer is that wet AMD is a chronic disease requiring ongoing management. The anti-VEGF treatment does not cure AMD — it suppresses the activity of the abnormal choroidal neovascularisation (CNV) that causes leakage and vision loss. When injections are stopped, CNV often reactivates. However, most patients do not require monthly injections indefinitely. Modern treat-and-extend (TAE) and treat-observe-extend (PRN) protocols allow the injection interval to be extended step by step — from monthly to 6-weekly, then 8-weekly, then 10-weekly, sometimes 12-weekly — based on OCT findings of disease activity. Many patients eventually achieve stable disease on an injection frequency of every 8–12 weeks.

The overall picture with anti-VEGF therapy for wet AMD is genuinely optimistic. Randomised controlled trials (ANCHOR, MARINA, VIEW) showed that ranibizumab maintained or improved visual acuity in over 90% of wet AMD patients at 2 years — a dramatic improvement over the natural history of untreated wet AMD, where severe vision loss occurs in the majority within the same timeframe. For patients in Patiala, consistent access to anti-VEGF treatment at Garg Eye Hospital without the need to travel to Chandigarh or Delhi makes a significant difference in treatment adherence and outcomes.

Lifestyle Factors and AMD Prevention in Patiala

While AMD cannot always be prevented, several modifiable risk factors can be addressed. Smoking is the single most important modifiable risk factor for AMD — smokers have a 2–4 times greater risk of developing AMD, and current smokers with AMD have worse outcomes. For patients in Patiala who smoke, cessation counselling is integrated into our AMD management programme.

A Mediterranean-style diet rich in leafy green vegetables (spinach, methi, sarson), coloured fruits, fish (omega-3 fatty acids), and nuts has strong epidemiological evidence for reducing AMD risk. Paradoxically, the traditional Punjabi diet — with its emphasis on dairy, legumes, and seasonal vegetables — contains many AMD-protective nutrients, though the shift toward refined foods and reduced vegetable consumption in urban settings is a concern. UV-protective sunglasses (reducing chronic blue and UV light exposure) are recommended for outdoor activities.